After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Implications for Fenofibrate
|
|
- Johnathan Rich
- 5 years ago
- Views:
Transcription
1 After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Implications for Fenofibrate Frank M. Sacks, MD The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study provides an extensive evidence base for the efficacy and tolerability of fenofibrate treatment in patients with type 2 diabetes mellitus, predominantly in a primary prevention setting. The FIELD study did not show a significant effect with fenofibrate on the primary end point, coronary artery disease death or nonfatal myocardial infarction (p 0.16). Treatment with fenofibrate did reduce all cardiovascular disease (CVD) events, the secondary end point (by 11%, p 0.035). The primary end point was reduced by the same percentage. The modest percent reduction in the primary and secondary end points is probably a result of a number of study confounders, notably an excess of statin drop-in therapy and disproportionate treatment with other drugs for CVD prevention in the placebo arm. Estimates of relative risk reduction used by the FIELD investigators to equalize the use of statins in the fenofibrate and placebo groups suggest a true benefit of treatment on reduction of CVD events of 17% 21%. There was no excess of elevated serum liver enzymes and no cases of rhabdomyolysis in patients receiving both fenofibrate and a statin. Prevention of microvascular disease, specifically, reduction in the rate of laser treatment for retinopathy (by 30%, p ), progression of albuminuria (p 0.002), and nontraumatic amputations (by 38%, p 0.011), may well be the most innovative finding of the FIELD study, especially in view of the current lack of effective preventative treatments for diabetic retinopathy and the need for additional treatments that slow the progression of diabetic nephropathy. These findings also give impetus to investigate mechanisms by which fenofibrate and peroxisome proliferator-activated receptor activation may protect the endothelium of small blood vessels in patients with type 2 diabetes Elsevier Inc. All rights reserved. (Am J Cardiol 2008;102[suppl]:34L 40L) The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study 1 was designed to investigate whether fenofibrate was broadly therapeutic in patients with type 2 diabetes mellitus, regardless of lipid profile. The pharmacologic profile of fenofibrate indicates activity against atherogenic dyslipidemia typically observed in type 2 diabetes or metabolic syndrome (ie, elevated triglyceride levels and low high-density [HDL] lipoprotein cholesterol levels). The design of the FIELD study was modeled on the Heart Protection Study. In the latter study, simvastatin, a drug that primarily lowers LDL cholesterol, was given to patients defined only by high risk of cardiovascular disease (CVD) and not by elevated plasma LDL cholesterol. 2 Thus, in the FIELD study, patients were enrolled if they had type 2 diabetes, a condition associated with high risk of CVD Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA; and the Cardiovascular Division and Channing Laboratory, Brigham and Women s Hospital, Boston, Massachusetts, USA. Statement of author disclosure: Please see the Author Disclosures section at the end of this article. Address for reprints: Frank M. Sacks, MD, Nutrition Department, Harvard School of Public Health, 655 Huntington Avenue, Building II, 3rd Floor, Boston, Massachusetts address: fsacks@hsph.harvard.edu. events, and not according to specific threshold concentrations of triglycerides or HDL cholesterol. They were randomized to treatment with fenofibrate or placebo against a background of usual care, including the option to add other lipid-lowering agents and drugs for CVD prevention. 1 This ethical approach was necessitated by findings from several studies before and during the FIELD study that showed that statins were beneficial in this setting. 3 5 The decision to initiate lipid-modifying therapy was based on the clinical judgment of the personal physician of each patient. A Low-Risk Patient Population Among populations of patients with type 2 diabetes, the FIELD study sample was considered to be at relatively low cardiovascular risk. At the start of the trial, most patients had been diagnosed with type 2 diabetes relatively recently (within a median of 5 years) and had a low prevalence of macrovascular and microvascular complications (22% and 21%, respectively). 1 The study population had good glycemic control at baseline, and this was maintained throughout the study (glycosylated hemoglobin was 6.9% at entry and at the end of study in the placebo group and 6.9% at entry /08/$ see front matter 2008 Elsevier Inc. All rights reserved. doi: /j.amjcard
2 Sacks/FIELD study and fenofibrate 35L Table 1 Baseline characteristics of patients with diabetes mellitus included in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, the Collaborative Atorvastatin Diabetes Study (CARDS), and the Heart Protection Study (HPS) FIELD (n 9,795) CARDS (n 2,838) HPS (n 5,963) Median duration of diabetes (yr) Cardiovascular disease (%) Microvascular complications (%) Retinopathy 8 30 NA Albuminuria 3 17 NA HbA 1c (%) Lipid parameters (mean) LDL cholesterol (mg/dl)* HDL cholesterol (mg/dl)* Triglycerides (mg/dl) Mixed dyslipidemia (%) 38 NA NA HbA 1c glycosylated hemoglobin; HDL high-density lipoprotein; LDL low-density lipoprotein; NA not available. * For cholesterol, 1 mg/dl mmol/l. For triglycerides, 1 mg/dl mmol/l. Mixed dyslipidemia was characterized by elevated triglycerides ( 150 mg/dl and HDL cholesterol 40 mg/dl in men and 50 mg/dl in women. and 7.0% at the end of study in the fenofibrate group). 1 Such good glycemic control was achieved at baseline by either diet (24%) or a single hypoglycemic drug (34%), and only 14% required insulin. 1 There was also a low prevalence of mixed dyslipidemia at baseline. Only 38% of patients had elevated triglycerides ( 150 mg/dl [1 mg/dl mmol/l]) and low HDL cholesterol ( 40 mg/dl in men and 50 mg/dl in women [1 mg/dl mmol/l]), common clinical criteria for the consideration of lipid-modifying treatment. 6 In contrast, patients with diabetes included in the Heart Protection Study and the Collaborative Atorvastatin Diabetes Study had a longer duration of diabetes, and higher glycosylated hemoglobin values at baseline (Table 1). 4,5 Confounding of Outcome Benefits The primary end point in the FIELD study was a composite of coronary artery disease (CAD) death and nonfatal myocardial infarction (MI). The effect of fenofibrate on this end point was nonsignificant (relative risk reduction [RRR], 11%; p 0.16). Although fenofibrate treatment significantly reduced the risk of nonfatal MI (by 24%, p 0.01), there was a nonsignificant excess of cardiac mortality (relative risk 19%, p 0.22). There was, however, a significant reduction in the secondary outcome, total CVD events (from 13.9% with placebo to 12.5% with fenofibrate; RRR, 11%; p 0.035). 1 This effect was largely driven by a significant RRR for nonfatal MI and the need for coronary revascularization (by 21%, p 0.003). 1 Figure 1. Changes in lipids in (A) the total Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study population, and in patient subgroups who (B) did not start and (C) did start lipid-lowering therapy. HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; TG triglycerides. (Adapted from Lancet. 1 ) It is possible that the higher than anticipated drop-in rate for other lipid-lowering treatment may have masked the effect of fenofibrate on the primary end point and contributed to the observed effect on cardiac mortality. The FIELD Investigators had planned for a 10% drop-in rate in the placebo group during the study. Instead, the use of nonstudy lipid-lowering therapy ( 90% statins) exceeded this; at study closure, 36% in the placebo group compared with 19% in the fenofibrate group were also receiving a statin. 1 In both treatment groups, patients who received add-on statin therapy showed a greater reduction in LDL cholesterol levels than those who did not (Figure 1). 1
3 36L The American Journal of Cardiology ( Vol 102 (12A) December 22, 2008 Figure 2. Changes in cardiovascular medication during the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ACE angiotensinconverting enzyme; ARB angiotensin II receptor blocker. *Significant differences at study close: lipid-lowering therapy, p ; ACE inhibitor, p 0.003; -blocker, p 0.011; digoxin, p 0.045; diuretic, p (Adapted from Lancet. 1 ) Concomitant medication data suggest that the standard of care was better for patients in the placebo group than the fenofibrate group. Along with greater use of lipid-modifying therapy, there was also more use of angiotensin-converting enzyme inhibitors, -blockers, diuretics, and antiplatelet drugs in the placebo group compared with the fenofibrate group (Figure 2). 1 It is possible that the improved management of patients in the placebo group may have accounted for the smaller number of coronary deaths in the placebo group than in the fenofibrate group (93 vs 110, respectively). 1 There was also a much greater use of statins in the patients who had a CVD event before starting the study, the secondary prevention cohort, compared with the primary prevention cohort. 1 Prescribing statins is a reasonable action by the patients primary care physicians in light of the beneficial results in patients with type 2 diabetes in large statin trials of secondary prevention published while the FIELD study was in progress. In contrast, statin use in the placebo group in the primary prevention cohort of the FIELD study was modest. It seems likely that this explains the significant reduction in CVD risk in the primary prevention cohort in which the placebo group was only minimally confounded by statin use. Taken together, it is likely that the combination of these factors may have obscured the full effect of fenofibrate. Modeling to take account of these confounders suggested a real underlying effect of fenofibrate on the primary outcome of 17% 21%. 1 Figure 3. The effect of fenofibrate, as defined by the number of patients needed to treat to prevent 1 adverse outcome (NNT), was greater in patients with mixed dyslipidemia than in those without. HDL-C high-density lipoprotein cholesterol. (Adapted from Lancet 1 and Circulation. 8 ) Pronounced Benefit in the Primary Prevention Setting As mentioned, subgroup analyses of the FIELD study data, including adjustment for statin use, showed that the benefit of fenofibrate was greater in patients with no prior CVD, both in the primary outcome (RRR, 25%; p 0.014), as well as total CVD events (RRR, 19%; p 0.004), compared with effects observed in patients with established CVD. 1
4 Sacks/FIELD study and fenofibrate 37L Figure 4. Effect of fenofibrate on laser treatment for diabetic retinopathy in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *p ; p ; p (Adapted from Lancet. 20 ) These findings were consistent with those observed in the Heart Protection Study, in which statin treatment of patients without prior CVD was associated with a greater proportional reduction in the risk of first major vascular events over 5 years than that observed among those with established CVD (33% vs 19%). 4 These findings support recommendations for early initiation of lipid-modifying treatment, in addition to lifestyle intervention, in patients with type 2 diabetes in order to prevent a first CVD event. 7 Greater Benefit in Mixed Dyslipidemia Only 38% of patients in the FIELD study had mixed dyslipidemia, defined by increased triglycerides ( 150 mg/dl) and low HDL cholesterol. 6 Subgroup analyses showed that treatment with fenofibrate was particularly beneficial in this subgroup of patients (absolute risk reduction, 2.3%; RRR, 14%; p 0.06). 1 In patients with mixed dyslipidemia, defined by elevated triglyceride ( 200 mg/dl) and low HDL cholesterol levels ( 40 mg/dl in men and 50 mg/dl in women), the benefit of treatment was even greater (absolute risk reduction, 4.3%; RRR, 26%; p 0.01). 8 It is especially notable that clinical benefit, expressed as the number needed to treat (the inverse of the absolute risk reduction), was 2-fold greater in each of these dyslipidemic subgroups (Figure 3). 1,8 Results from other fibrate studies are consistent with this finding. For example, in the Helsinki Heart Study, a primary prevention study, the benefit of gemfibrozil treatment (1,200 mg/day) in patients with mixed dyslipidemia (triglycerides 204 mg/dl and LDL/HDL ratio 5) was twice that observed in the total study population, with an RRR for major coronary events of 71% (p 0.005) compared with 34% (p 0.02 in all patients). 9,10 Additionally, subgroup analysis of the Bezafibrate Study, a secondary prevention trial, showed enhanced benefit with bezafibrate in patients with the metabolic syndrome and mixed dyslipidemia (baseline HDL cholesterol, 33 mg/dl; and triglycerides, 170 mg/dl), with a 25% RRR (p 0.03) for cardiovascular events compared with a nonsignificant effect in all study patients. 11 Moreover, there was even greater benefit in patients with triglycerides 200 mg/dl (RRR, 39.5%; p 0.02). 12 The Veterans Affairs HDL Intervention Trial (VA-HIT) also demonstrated significantly greater reduction in cardiovascular risk with gemfibrozil treatment in CAD patients with diabetes and mixed dyslipidemia (RRR, 32%; p 0.004) compared with those without diabetes (RRR, 18%; p 0.07). 13 Thus, evidence of improved clinical benefit with fibrate therapy in patients with mixed dyslipidemia associated with type 2 diabetes or metabolic syndrome in the FIELD study and other fibrate trials reinforces current therapeutic practice to target fibrate treatment to these patient groups. 8,14,15 Other Findings from the Fenofibrate Intervention and Event Lowering in Diabetes Study Treatment with fenofibrate also led to reduction in hospitalization for angina pectoris (from 5.1% with placebo to 4.3%; RRR, 18%; p 0.04). 16 Acute coronary syndromes, including unstable angina, are prevalent and confer substantial adverse prognosis in patients with diabetes. Subgroup analyses from 11 Thrombolysis in Myocardial Infarction (TIMI) study group clinical trials conducted from showed that of 62,036 patients admitted with acute coronary syndromes, 17% had diabetes. Mortality at 30
5 38L The American Journal of Cardiology ( Vol 102 (12A) December 22, 2008 days was significantly higher in these patients than in those without diabetes (2.1% vs 1.1%, p 0.001). The 1-year mortality was also 65% higher in patients with diabetes and acute coronary syndromes (hazard ratio, 1.65; 95% confidence interval, ). 17 The finding that fenofibrate was effective in reducing hospitalization for unstable angina in this predominantly low-risk population is promising and warrants further investigation. Microvascular Effects Although macrovascular atherosclerotic disease is the main cause of mortality in patients with type 2 diabetes, microvascular complications are also common and associated with substantial morbidity. In the United States, diabetes is the leading cause of blindness and vision loss, end-stage renal disease, and nontraumatic amputations. 18 Moreover, given the increasing prevalence of diabetes (and metabolic syndrome) among an aging population, 19 the burden attributable to microvascular complications is likely to increase considerably in the future. The FIELD study has demonstrated, for the first time for any lipid-modifying therapy, a significant reduction in the progression of diabetes-related retinopathy. There was a 30% reduction in the rate of laser treatment for retinopathy with fenofibrate treatment (from 5.2% to 3.6%, p ). This effect was evident within the first year of treatment, and it increased over the 5-year period of the study. 1 In a recent analysis of the FIELD study retinopathy data, treatment with fenofibrate was shown to have a significant effect in reducing first laser treatment in patients with macular edema (from 3.4% to 2.4%; RRR, 31%; p 0.002), as well as those with proliferative retinopathy (from 2.2% to 1.5%; RRR, 30%; p 0.015). In patients without prior retinopathy, there was an even greater benefit (RRR, 39%; p ) (Figure 4). 20 These positive findings gain validity from the fact that the investigators hypothesized benefit during the planning of the study and included retinopathy as a prospectively specified end point in the protocol. This hypothesis in part stemmed from early reports of favorable effects on diabetic eye disease with another fibrate, clofibrate. 21 Fenofibrate treatment was also associated with other microvascular benefits. There was significant reduction in the evolution of albuminuria (with a decrease by 14% in the proportion of patients showing progression and an increase by 15% in those showing regression of albuminuria, p 0.002). 1 These data support preliminary findings from the Diabetes Atherosclerosis Intervention Study (DAIS), in which treatment with fenofibrate significantly attenuated the worsening of albumin excretion in patients with type 2 diabetes, 22 discussed elsewhere in this supplement in an article by Dr. George Steiner. 23 In addition, treatment with fenofibrate significantly reduced the number of nontraumatic amputations for peripheral artery disease by 38% (p 0.011), which reflects both macrovascular and microvascular benefits. 16 These data suggest that fenofibrate may have favorable effects on small vessel repair and/or protect against capillary damage or leakage. In fact, recent in vitro data indicate that fenofibrate regulates retinal endothelial cell survival via the adenosine monophosphate activated protein kinase signal transduction pathway, suggesting an effect on retinal leakage independent of lipid effects. 24 As alluded to by Keech et al, 20 further studies are clearly required to investigate the mechanism(s) of these effects reported by the FIELD study. Tolerability Profile Consistent with available evidence, 25 the FIELD study data show that fenofibrate is a well-tolerated treatment. Although there was a small increase in rare adverse events of pancreatitis (0.8% vs 0.5%, p 0.031) and pulmonary embolism (1.1% vs 0.7%, p 0.022), there were no other significant adverse events. 1 Findings relating to pancreatitis are not inconsistent with the activity of fibrates, which have all been shown to stimulate increased biliary excretion of cholesterol, leading in turn to a substantial increase in the biliary cholesterol saturation index. 26 The effect of fenofibrate on pulmonary embolism, however, has not been reported in other studies of fenofibrate or fibrates in general and is still under investigation by the FIELD Study Scientific Committee. The potential for myopathy is a concern in fibrate therapy, although evidence suggests that the risk is much lower with fenofibrate than with other fibrates, such as gemfibrozil. Data from the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) over the period showed that the rate of rhabdomyolysis was 10-fold lower with fenofibrate monotherapy compared with gemfibrozil monotherapy (5.5 vs 59.6 per million prescriptions dispensed for each agent). In addition, the rate of myopathy (excluding rhabdomyolysis) was about 2-fold lower with fenofibrate compared with gemfibrozil (8.8 vs 15.7 per million prescriptions dispensed). 27 Data from the FIELD study are consistent with this favorable tolerability profile. There was no significant difference between the placebo and fenofibrate groups in the incidence of elevation in creatine phosphokinase ( 10 upper limit of normal, 3 vs 4 patients, respectively) or rhabdomyolysis (1 vs 3 patients, respectively). 1 In patients with mixed dyslipidemia common in type 2 diabetes or metabolic syndrome, the combination of a fibrate and a statin is a recommended strategy for achieving all lipid targets. 7,14 Concern about the risk of myopathy when these agents are administered together may, however, limit the use of this combination. The evidence supports a lower potential risk for myopathy with the combination of fenofibrate and a statin compared with gemfibrozil and a statin. Data from the FDA AERS show that when administered with a statin, fenofibrate combination therapy was
6 Sacks/FIELD study and fenofibrate 39L associated with a 15-fold lower risk of rhabdomyolysis than gemfibrozil statin combination therapy (8.6 vs 0.58 cases per million prescriptions dispensed) (data for cerivastatin excluded). 28 Furthermore, there were no cases of rhabdomyolysis in about 1,000 patients in the FIELD study who received both fenofibrate and statin. 1 Experimental studies show that, unlike fenofibrate, gemfibrozil and statins are both metabolized by the same family of glucuronidases. 29 These data suggest a much higher likelihood of pharmacokinetic drug interaction when gemfibrozil rather than fenofibrate is administered with a statin, as confirmed in recent pharmacokinetic interaction studies. 30 During the FIELD study, plasma creatinine levels were on average higher by mol/l in the fenofibrate than placebo groups, although in a subset of patients restudied 8 weeks after discontinuing study treatment, plasma creatinine levels had decreased to levels below those observed in the placebo group. 1 However, fenofibrate was associated with significant reduction in progression of albuminuria in the FIELD and DAIS studies 1-3 (see above), indicating no impairment of renal function during the 5 years of fenofibrate treatment. There was also a small nonsignificant excess of non- CVD deaths with fenofibrate. This was investigated by the FIELD study investigators. However, because there was no evidence that this finding was attributable to any specific cause of death or linked to any significant increase in any specific nonfatal non-cvd event, such as invasive cancer, the FIELD study investigators concluded that this was a chance finding. Taken together, the FIELD study adds to the available evidence supporting guideline recommendations 7,31 that fenofibrate is a well-tolerated treatment option in dyslipidemia management in type 2 diabetes, most likely in combination with a statin. Moreover, a recent health economic analysis of the FIELD study conducted from the perspective of the third party payer, showed that fenofibrate therapy resulted in an approximate 10% reduction in healthcare costs driven mainly from decreases in nonfatal MI risk and coronary revascularization, or supplementary statin therapy. 32 These data suggest potential longer-term cost advantages associated with initiation of fenofibrate therapy in this patient population. Although the FIELD study provides some data on the combination of fenofibrate with a statin, there is also a clear need for data from ongoing outcomes studies to evaluate the efficacy and tolerability of this combination. Conclusion The FIELD study aimed to evaluate the role of fenofibrate therapy in reducing CVD risk in patients with type 2 diabetes, predominantly in a primary prevention setting. In this study population, fenofibrate treatment was associated with significant macrovascular and microvascular benefits. Although it is acknowledged that the study failed to show a significant beneficial effect on the primary outcome (major coronary events), a number of confounders may have contributed to this finding. The FIELD study data need to be considered within the context of statin therapy, which is the main focus of dyslipidemia management in patients with diabetes or metabolic syndrome. Although statins are effective in lowering LDL cholesterol, a substantial proportion of patients fail to achieve all recommended lipid targets, most notably those for triglycerides, HDL cholesterol, and non-hdl cholesterol, and they remain at higher cardiovascular risk. The FIELD study data suggest that the addition of fenofibrate to statin therapy may be a logical, well-tolerated option for reducing this residual risk. Furthermore, the FIELD study indicates that early initiation of fenofibrate treatment may prevent or limit the development of diabetes-related microvascular complications, specifically, retinopathy and nephropathy, which confer substantial disease morbidity. Clearly, further study is needed to evaluate whether this combination provides outcome benefits and is safe. We await with interest the results of ongoing studies, the first of which (ACCORD) 33 are expected in Key points: Fenofibrate may be effective in reducing cardiovascular risk in patients with type 2 diabetes, particularly in those with mixed dyslipidemia Fenofibrate is well tolerated Treatment with fenofibrate provides microvascular benefits; these effects require further study Early initiation of fenofibrate (most likely in addition to a statin) is likely to be of greatest benefit in the primary prevention setting Author Disclosures Frank M. Sacks, MD, has received research support from ISIS and honoraria for consultancy to Abbott Laboratories, Aegerion, AstraZeneca, Genzyme, ISIS, Johnson & Johnson, Lilly, Lipid Sciences, Merck, and Solvay; has received honoraria for lectures from Abbott Laboratories, AstraZeneca and Solvay; is a shareholder of Lipid Sciences. 1. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glosziou P, et al, for the FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD trial): randomised controlled trial. Lancet 2005;366: Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360: Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD. Effect of pravastatin on coronary disease events in subgroups defined by coronary
7 40L The American Journal of Cardiology ( Vol 102 (12A) December 22, 2008 risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102: Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, for the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet 2004;364: Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A, for the FIELD Study Investigators. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and shortterm effects of fenofibrate. Cardiovasc Diabetol 2005;4: Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, et al, for the American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a Scientific Statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115: Scott R, d Emden M, Best J, Drury P, Ehnholm C, Kesaniemi A, Pardy C, Tse D, Barter P, Taskinen MR, Copt S, Keech A, on behalf of the FIELD Investigators. Features of metabolic syndrome identify individuals with type 2 diabetes mellitus at high risk for cardiovascular events and greater absolute benefits of fenofibrate. Circulation 2007;116:II Abstract Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85: Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317: Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165: Bezafibrate Infarction Prevention Study Investigators. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bazafibrate Infarction Prevention (BIP) study. Circulation 2000;102: Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002;162: National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002;106: Smith SC, Allen J, Blair SN, Bonow RO, Brass LW, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006; 113: Burgess D, Hunt D, Li LP, Zhang J, Sy R, Laakso M, Davis T, Colman P, Forder P, Williamson E, Pike R, Keech A, on behalf of the FIELD Investigators. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [abstract]. Circulation 2007;116:II Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA 2007;298: a.National Diabetes Statistics. Available at: diabetes.niddk.nih.gov/dm/ pubs/statistics/index.htm. Accessed March 28, b.Center for Disease Control. Lower extremity disease among persons aged 40 years with and without diabetes United States, Available at: Accessed June 29, Diabetes atlas. Available at: Accessed June 17, Keech AC, Mitchell P, Summanen PA, O Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, et al, for the FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370: Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969; 18: Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DIAS). Am J Kidney Dis 2005; 45: Steiner G. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. Am J Cardiol 2008;102(suppl): 28L 33L. 24. Kim J, Ahn JH, Kim JH, Yu YS, Kim HS, Ha J, Shinn SH, Oh YS. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007;84: Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007;67: Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99(suppl):3C 18C. 27. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004;94: Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate statin versus gemfibrozil any statin. Am J Cardiol 2005;95: Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30: Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005;96(suppl):44K 49K. 31. American Diabetes Association. Standards of medical care in diabetes Diabetes Care 2008;31(suppl 1):S12 S Carrington M, Stewart S. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD study. Int J Cardiol 2008;127: Buse JB, Bigger JT, Byington RP, for the ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes trial: design and methods. Am J Cardiol 2007;99(suppl):21i 33i.
( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationWhen it comes to the FIELD study, what is...is
Future Lipidology ISSN: 1746-0875 (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/tlip19 When it comes to the FIELD study, what is...is James McKenney To cite this article: James McKenney
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationΟ ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη
Ο ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη Κωνσταντίνος Τζιόμαλος Επίκουρος Καθηγητής Παθολογίας Α Προπαιδευτική Παθολογική Κλινική, Νοσοκομείο
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationLow HDL C and/or elevated triglycerides (TG) was seen in nearly two thirds of MI patients
PRESS RELEASE New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL Cholesterol Surveys establish residual
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationIMPORTANCE OF HIGH TRIGLYCERIDES AS A CARDIOVASCULAR RISK FACTOR IN INDIAN DIABETIC POPULATION A REVIEW
IMPORTANCE OF HIGH TRIGLYCERIDES AS A CARDIOVASCULAR RISK FACTOR IN INDIAN DIABETIC POPULATION A REVIEW Hiren Pandya Department of Medicine, AMC MET Medical College, Ahmedabad, Gujarat, India Correspondence
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationFibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit
Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationLink between effectiveness and cost data The effectiveness and cost data came from the same sample of patients and were prospectively evaluated.
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS) Raikou M, McGuire A, Colhoun
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationGUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES
GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES Prepared by DCPNS Action Committee Dr. Lynne Harrigan Brenda Cook Peggy Dunbar Bev Harpell with the assistance
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationUse of Subgroups to Rescue a Trial or Improve Benefit-Risk
1 Use of Subgroups to Rescue a Trial or Improve Benefit-Risk Martin King, Ph.D. Director, Statistics Global Pharmaceutical R&D, Abbott Abbott Park, IL USA 2 Disclaimer The opinions in this presentation
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More informationDiabetes mellitus type 2 and angina pectoris : novel insights in diagnosis, prognosis and treatment Wiersma, J.J.
UvA-DARE (Digital Academic Repository) Diabetes mellitus type 2 and angina pectoris : novel insights in diagnosis, prognosis and treatment Wiersma, J.J. Link to publication Citation for published version
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationRisk Factors and Primary and Secondary Prevention of Coronary Heart Disease
Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationRaising high-density lipoprotein cholesterol: where are we now?
European Heart Journal Supplements (23) 5 (Supplement D), D17 D25 Raising high-density lipoprotein cholesterol: where are we now? Baylor College of Medicine, Houston, Texas, U.S.A. KEYWORDS Apolipoprotein;
More informationThe cholesterol challenge(s) in cardiovascular risk in 2014
The cholesterol challenge(s) in cardiovascular risk in 2014 Alberto Zambon University of Padova - Italy Italy University of Padova The Oldest Medical School in the World (established in a.d. 1222) The
More informationLow HDL and Diabetic Dyslipidemia
The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted
More informationJournal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.
Journal of the American College of Cardiology Vol. 54, No. 25, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.005
More informationThis is a lipid lowering drug strategy which should only be used within an overall lifestyle and clinical management strategy.
Treatment Guideline Statin Prescribing Objective These guidelines represent the views of the Gloucestershire Hospitals NHS Foundation Trust, which were arrived at after consideration of the available evidence
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationDiabetes mellitus is a leading cause of morbidity and
Clinical Guidelines Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians Vincenza Snow, MD; Mark D. Aronson, MD; E. Rodney
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationFibrate and cardiovascular disease: Evident from meta-analysis. Thongchai Pratipanawatr
Fibrate and cardiovascular disease: Evident from meta-analysis Thongchai Pratipanawatr ??? ย คห นใหม ย คห นกลาง ย คห นเก า ?? Statin era? ย คห นใหม ย คห นกลาง ย คห นเก า CURRENT ROLE OF FIBRATE What are
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationAttainment of Combined Optimal Lipid Values With the Use of Niacin
www.medscape.com Attainment of Combined Optimal Lipid Values With the Use of Niacin Has AIM-HIGH Closed the Book on This Debate? Tyan Thomas Clin Lipidology. 2012;7(4):389-396. Abstract and Introduction
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationReducing the risks in diabetes
Centre for Clinical and Basic Research, Department of Medical Sciences and Rehabilitation, IRCCS San Raffaele, Rome, Italy Correspondence: Dr Giuseppe Rosano, Department of Medical Sciences and Rehabilitation,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationWelcome! Mark May 14, Sat!
Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationComparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin
Comparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin on C-Reactive Protein and Lipoproteins in Patients With Angiographic Evidence of Coronary Arterial Narrowing Kent G. Meredith,
More informationCardiovascular outcomes in type 2 diabetes: the impact of preventative therapies
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: The Year in Diabetes and Obesity Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies Sophia
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationCardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More informationEFFECT OF GOOD GLYCEMIC CONTROL ON LIPID PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS IN AL HUSSEIN TEACHING HOSPITAL
Thi-Qar Medical Journal (TQMJ): Vol(5) No(2):2011(39-44) EFFECT OF GOOD GLYCEMIC CONTROL ON LIPID PROFILE IN TYPE 2 DIABETES MELLITUS PATIENTS IN AL HUSSEIN TEACHING HOSPITAL Dr. Akeel bal-yaqobi *, Dr.
More informationEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. The ACCORD Study Group* Abstract
The new england journal of medicine established in 1812 april 29, 21 vol. 362 no. 17 Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus The ACCORD Study Group* Abstract Background We investigated
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More informationStatin-Fenofibrate Combination Therapy in an ACCORD Population: A Retrospective Analysis Nair, Zachry, hume, and clarke
Volume 4, Number 5 September/October 2012 Practical Implications p 210 Author Information p 215 Full text and PDF www.ajpblive.com Translating Evidence-Based Research into Value-Based Decisions from the
More informationSOLVAY GROUP London Morning Meeting. June 26, 2009
SOLVAY GROUP London Morning Meeting June 2, 9 1 Our fenofibrate franchise Klaus Kirchgassler, MD Sr VP Solvay Pharmaceuticals 2 Summary of lipid lowering market performance in Value Growth vs. previous
More informationOn May 2001, the Third Adult
THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists
More informationStrategies for the prevention of type 2 diabetes and cardiovascular disease
European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More information